louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02044731: Impact of a Childhood Obesity Intervention for African American Families
Official title: Impact of a Childhood Obesity Intervention for African American Families
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Overweight
Keywords: Schools
Pediatrics
Obesity
Overweight
Intervention Studies
African Americans
Family
Body mass index
Lead sponsor: University of California, Berkeley
Sponsor class: OTHER
First posted: 2014-01-24
Enrollment: 19
Sex: ALL
Minimum age (years): 5
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the impact on body mass index (BMI) of a 5-session childhood obesity intervention for African American families among children aged 5-12 years. We hypothesize that children participating in the program will experience a reduction in BMI.


Eligibility criteria: Inclusion Criteria:

* BMI greater than or equal to the 85th percentile for age and sex
* Attends an elementary school in the Pittsburg Unified School District in California
* Parent of child meeting above criteria

Exclusion Criteria:

-

Primary outcomes:
measure: Body mass index (BMI)
timeFrame: Baseline and at week 10
Secondary outcomes:
measure: Blood pressure
timeFrame: Baseline and at week 10
Other outcomes:
measure: Parent weight
timeFrame: Baseline and at week 10
measure: Parent reported behaviors
timeFrame: Baseline and at 10 weeks
measure: Parent blood pressure
timeFrame: Baseline and at week 10
Locations:
city: Pittsburg
country: United States
facility: Parkside Elementary School
state: California
Study officials:
affiliation: University of California, Berkeley
name: Kristine A Madsen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04868331: Cardiovascular Responses in Adolescent Idiopathic Scoliosis Girls
Official title: Evaluation of Cardiovascular Responses in Adolescent Idiopathic Scoliosis (AIS) Girls Performing E-Fit Exercise Intervention: a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Adolescent Idiopathic Scoliosis
Lead sponsor: Tung Wah College
Sponsor class: OTHER
Collaborators: name: Chinese University of Hong Kong
First posted: 2021-04-30
Enrollment: 20
Sex: FEMALE
Minimum age (years): 10
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The aims of this pilot study are to determine the metabolic demand and exercise intensity level of E-Fit exercise intervention by evaluating the cardiovascular responses in AIS girls and whether the cardiovascular responses for AIS girls performing E-Fit will behave in the same way as compared to healthy controls. We hypothesise that 1) the metabolic demand and exercise intensity of E-Fit exercise intervention is equivalent to moderate-to-vigorous level; and 2) AIS girls have different cardiovascular responses as compared to healthy controls

Detailed description: AIS girls and age- and gender-matched healthy controls will perform the E-Fit exercise intervention for two trials and gas exchange parameters including oxygen consumption (VO2) and carbon dioxide production (VCO2) will be taken continuously during the exercise. Comparison of VO2 and VCO2 between AIS and healthy controls when performing E-Fit exercise will be made.

Eligibility criteria: Inclusion Criteria:

* Cobb angle greater or equal to 15 degree
* Cleared for physical activity by doctor

Exclusion Criteria:

* Cobb angle greater or equal to 40 degree, or
* Scoliosis with any known etiology, scoliosis with skeletal dysplasia, know endocrine and connective tissue abnormalities, or
* Known heart condition or other diseases that could affect the safety of exercise, or
* Eating disorders or GI malabsorption disorders, or
* Currently taking medication that affects bone or muscle metabolism

Primary outcomes:
measure: Respiratory gas measurement
timeFrame: Day 1
measure: Blood Pressure
timeFrame: Day 1
measure: Heart rate
timeFrame: Day 1
measure: Oximetry
timeFrame: Day 1
Secondary outcomes:
measure: Maturity assessment
timeFrame: Day 1
measure: Modified Baecke Questionnaire
timeFrame: Day 1
measure: Physical Activity Rating Questionnaire for Children and Youth (PARCY)
timeFrame: Day 1
measure: Body height
timeFrame: Day 1
measure: Sitting height
timeFrame: Day 1
measure: Arm Span
timeFrame: Day 1
measure: Body Composition
timeFrame: Day 1
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Tung Wah College
Study officials:
affiliation: Tung Wah College
name: Rufina Lau, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07027631: Comparative Efficacy of Magnesium Sulfate Iontophoresis and Extracorporeal Shockwave Therapy on Chronic Mechanical Neck Pain
Official title: Comparative Efficacy of Magnesium Sulfate Iontophoresis and Extracorporeal Shockwave Therapy on Chronic Mechanical Neck Pain. A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Mechanical Neck Pain
Keywords: shock wave therapy
Magnesium Sulfate iontophoresis
low back pain
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2025-06-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to investigate the Comparative Efficacy of Magnesium Sulfate Iontophoresis and Extracorporeal shockwave therapy on Chronic Mechanical Neck Pain


Eligibility criteria: Inclusion Criteria:

* medically competent men and women will be included
* They had chronic MTrPs in the upper trapezius for more than 6 months
* Diagnostic criteria of being a tight band with a palpable nodule and distant pain when subjected to pressure

Exclusion Criteria:

* subjects with previous neck or shoulder pathology (e.g., fracture, sur¬gery, inflammatory and infectious diseases),
* cervical disc pathology, systemic disorder, fibromyalgia,
* those who underwent physical therapy for at least the previous 3 months

Primary outcomes:
measure: pain pressure threshold
timeFrame: 0-4 weeks
measure: Pain intensity
timeFrame: 0-4 weeks
Secondary outcomes:
measure: Neck Disability Index
timeFrame: 0-4 Weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01987531: Temporary Biventricular Pacing
Official title: Hemodynamic Effect of Temporary Biventricular Pacing After Mitral and/or Tricuspid Valve Surgery in Patients With Preoperative Biventricular Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Right Ventricular (RV) Dysfunction
Keywords: after open cardiac chamber cardiac surgery
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2013-11-19
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 84
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The hypothesis of this study is that temporary biventricular pacing will improve hemodynamic performance in patients with right ventricular dysfunction after open cardiac chamber cardiac surgery.


Eligibility criteria: Inclusion Criteria:

* mitral or tricuspid valve surgery patients identified as having preoperative Right Ventricular dysfunction and Left Ventricular Ejection Fraction less than 45 percent

Exclusion Criteria:

* Patients with in-situ biventricular pacemakers
* Pregnant or lactating females

Primary outcomes:
measure: Right ventricular function of the heart
timeFrame: 24 hours after cardiac surgery completion
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania, Anesthesia
name: William Vernick, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00681382: Asthma Patient Survey Study to Assess Asthma Effect and Medication in Finland
Official title: INSPIRE Asthma Patient Survey to Clarify the Use of Asthma Medication and Effects of Asthma in Everyday Life in Finland
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Keywords: Asthma
use of asthma medication
asthma control
telephone survey
patient's perception
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-05-21
Enrollment: 142
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care clinic

Brief summary: This study was aimed at clarifying how the asthma medication is used in practice and how asthma affects everyday life. Total of 106 GPs were asked to recruit patients using inhaled steroid as maintenance treatment for asthma to take part in a telephone survey. Altogether 142 patients were interviewed.


Eligibility criteria: Inclusion Criteria:

* Diagnosed persistent asthma
* regular use of inhaled steroids and concomitant medication

Exclusion Criteria:

* never been diagnosed COPD
* seasonal asthma

Primary outcomes:
measure: Patients perceptions about treatment of asthma, asthma medication and what are the most common triggers that cause exacerbations.
timeFrame: Single occasion
Secondary outcomes:
measure: How patients react to the first signs of worsening of asthma i.e. how they use asthma medication during stable phase and asthma exacerbation
timeFrame: Single occasion
measure: How asthma affects everyday life
timeFrame: Single occasion
Other outcomes:
Locations:
Study officials:
affiliation: AstraZeneca Finland
name: Airi Puhakka
role: STUDY_DIRECTOR
affiliation: South Karelia Central Hospital, Finland
name: Jouni Hedman
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04885582: The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation
Official title: The Relationship Between HLA Tissue Compatibility and Biliary Complications in Patients With Liver Transplantation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Transplant; Complications
HLA Antigens
Keywords: Liver Transplant
Complications
HLA
biliary fistula
biliary stricture
Lead sponsor: Inonu University
Sponsor class: OTHER
First posted: 2021-05-13
Enrollment: 80
Sex: ALL
Minimum age (years): 1
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who had liver transplantation and HLA tissue tests between 2017 and 2019 at Inonu University liver transplant institute

Brief summary: Liver transplantation has become the accepted treatment option for advanced liver failure in recent years. In addition to the increase in the number of centers performing transplant and the decrease in complication rates depending on the experience gained, the most common biliary complications did not improve at the desired level. For this reason, studies in this field are frequent today.

The structural complexities of HLA antigens have been the subject of investigation in recent years. With the development of DNA and RNA amplification methods; It is increasingly difficult for physicians to keep up with the increasing burden of knowledge regarding the genetic aspects of these antigens. Concrete benefits of this gene complex, which has been investigated in various fields and preserves its mystery, have not been determined in liver transplant patients. However, there are publications showing its connection with the bile epithelium in liver transplantation and its relationship with the disappearing bile duct syndrome. In this study, our aim is to explain whether the bile duct complications, which appear like a continuous wall and can lead to frightening pictures, are related to HLA tissue compatibility.


Eligibility criteria: Inclusion Criteria:

* patients with liver transplantation and tested for HLA antigen (recipient - donor)

Exclusion Criteria:

* patients who died early Patients whose HLA antigen is not checked

Primary outcomes:
measure: Bliary complications
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Kocasinan
country: Turkey
facility: Health science University - Kayseri State Hospital
state: Kayseri
Study officials:
References:
Clinical trial NCT04296682: Impact Of Soft Tissue Manipulation On Dimensional Changes After Posterior Region Extraction.
Official title: Impact Of Soft Tissue Manipulation On Dimensional Changes After Posterior Region Extraction: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Alveolar Ridge Preservation
Connective Tissue
Lead sponsor: University of Campinas, Brazil
Sponsor class: OTHER
First posted: 2020-03-05
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Alveolar preservation seek to avoid multiple surgical interventions to the patient and decrease costs to the patient. In particular, in a Brazilian population where the need for extraction is great, the development of techniques that safely allow a higher quality of rehabilitation is of paramount importance. Thus, this analysis is of great scientific and therapeutic importance. Within the above, the objective is to use an autogenous connective tissue graft in order to eliminate the need to raise the full-thickness flap and compensate for soft tissue deficiencies, which may reduce dimensional losses after extraction, in addition to reducing the cost of the technique.


Eligibility criteria: Inclusion Criteria:

* Systemic health (absence of Hypertension and Diabetes);
* Indication of dental extraction of at least 2 teeth (with at least 2/3 of bone support, in the region of premolars or molars with indication for extraction;
* Signature of the consent form;
* Individuals over 18 years old.

Exclusion Criteria:

* Presence of periodontal disease at the time of surgery;
* Pregnant and lactating women;
* Smokers;
* Be under orthodontic treatment;
* Use medication that alters the bone healing process, such as those used to treat osteoporosis and the bisphosphonates group;
* Individuals under 18 years old.

Primary outcomes:
measure: Minor Alveolar dimensional loss with gingival graft.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Piracicaba
country: Brazil
facility: University of Campinas, UNICAMP
state: Sao Paulo
Study officials:
References:
Clinical trial NCT00844831: Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Official title: Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Constipation
Keywords: Constipation
small intestinal bacterial overgrowth
stool bacteria
Lead sponsor: University of Louisville
Sponsor class: OTHER
Collaborators: name: Takeda
First posted: 2009-02-16
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients with constipation often have bloating and abdominal distension. It is unclear if this is related to intestinal bacteria. Hypothesis: treatment for constipation may reduce small bowel and colon bacteria colonization, a change in the balance of stool microorganisms, and improve the symptoms of dyspepsia and constipation.

Detailed description: This is an open-label study to collect data on upper and lower GI symptoms, hydrogen breath test, stool PCR, and serum before and after 4 weeks of lubiprostone 24 mcg by mouth twice a day for 4 weeks.

Eligibility criteria: Inclusion Criteria: Functional constipation by Rome III criteria

Exclusion Criteria:

1. History of esophageal or gastric surgery (including vagotomy, antireflux, and obesity surgery)
2. History of small bowel or colon resection (excluding appendectomy and cholecystectomy)
3. History of gastric outlet, small bowel, or colon obstruction
4. History of surgery for small bowel adhesion lysis
5. History of surgery for gastroparesis
6. Diagnosis of diabetes requiring daily medications
7. Diagnosis of connective tissue d/o (including scleroderma, lupus, mixed connective tissue disorder)
8. Diagnosis of neuromuscular disorder (including multiple sclerosis, Parkinson, muscular dystrophy, dysautonomia, dystonia)
9. Disorders of small bowel pseudo-obstruction or dumping syndrome
10. Untreated or poorly controlled hypothyroidism
11. Taking an opiate medication daily
12. Taking a medication daily that can cause constipation (calcium channel blocker, anticholinergic, iron supplements, etc.)
13. Active cancer being treated
14. History of significant liver, kidney, cardiac disease that may interfere with study compliance
15. Known allergy or side effects to lubiprostone
16. Non-ambulatory patients: bed-ridden, nursing home resident, etc.

Primary outcomes:
measure: Presence of Small Intestinal Bacterial Overgrowth
timeFrame: 28 days
Secondary outcomes:
measure: Small Bowel and Colon Transit Time by SmartPill® Transit Study
timeFrame: 28 days
measure: Small Intestinal Bacterial Overgrowth (SIBO)
timeFrame: 28 days
Other outcomes:
Locations:
city: Louisville
country: United States
facility: University of Louisville
state: Kentucky
Study officials:
affiliation: University of Louisville
name: John Wo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01207531: MiRNAs Evaluate the Prognosis of Sepsis
Official title: miRNA in the Evaluation of the Value of Sepsis Prognosis Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sepsis
Keywords: sepsis
miRNA
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2010-09-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: within 24 hours after admited in ICU

Brief summary: Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to screen several miRNA by microarray which evaluate the sepsis prognosis in order to be a new target for the treatment of sepsis.

Detailed description: The study is a non-intervention, prospective observational study. Purpose of this sudy is to screening several miRNAs by microarray which can evaluate the prognosis of sepsis . We will collect serum samples from patients with sepsis in SICU, RICU and EICU of 301 Hospital since September 2009 , and then use the chip and qRT-PCR to Screen miRNAs which can evaluate the prognosis of sepsis, and statistical analysis the miRNAS expression correlation with SOFA score.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of sepsis
* Patients who agree with the study

Exclusion Criteria:

* Aged \<18 years;
* Into the group who died within 24 hours;
* Agranulocytosis (\<0.5 × 109 / L);
* Combined HIV infection.

Primary outcomes:
measure: all cause mortality
timeFrame: 28days after admited in ICU
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Chinese PLA General Hospital
state: Beijing
Study officials:
affiliation: Pneumology Department of chinese PLA General Hospital
name: Lixin Xie, Doctor
role: STUDY_DIRECTOR
References:
citation: Wang H, Zhang P, Chen W, Feng D, Jia Y, Xie L. Serum microRNA signatures identified by Solexa sequencing predict sepsis patients' mortality: a prospective observational study. PLoS One. 2012;7(6):e38885. doi: 10.1371/journal.pone.0038885. Epub 2012 Jun 15.
Clinical trial NCT00839631: Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors
Official title: A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Enteric Coated D-3263 Hydrochloride in Subjects With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumors
Keywords: subjects with advanced solid tumors refractory to standard therapy or for whom no effective therapy is available.
Lead sponsor: Dendreon
Sponsor class: INDUSTRY
First posted: 2009-02-09
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 1, dose escalation study evaluating safety and pharmacokinetics of enteric coated D-3263 HCl in subjects with advanced solid tumors


Eligibility criteria: Inclusion Criteria:

* histologically or cytologically confirmed advanced solid tumor malignancy which is either refractory to standard therapy or for which no standard therapy exists
* measurable or evaluable disease
* \>= 18 years of age
* ECOG of 0, 1 or 2
* no treatement with chemotherapy, radiotherapy or other systemic therapy (excluding depot LHRH agonist or antagonist for subjects with prostate cancer) for the treatment of his or her tumor with in 28 days prior to receipt of EC D-3263 HCl

Exclusion Criteria:

* Clinically significant coronary artery disease or conduction system abnormality
* Coagulation disorder
* Active infection requiring the use of systemic antimicrobial medications within seven days prior to receipt of EC D-3263 HCl
* Any major surgery within 28 days prior to receipt of EC D-3263 HCl

Primary outcomes:
measure: Assess the safety of EC D-3263 HCl
timeFrame: weekly
measure: Determine the maximum tolerated dose of EC D-3263 HCl administered orally daily
timeFrame: weekly
Secondary outcomes:
measure: Characterize the pharmacokinetic profile of EC D-3263 HCl after a single dose and repeat daily dosing
timeFrame: periodically within the first month, weekly thereafter
measure: preliminary assessment of antitumor activity
timeFrame: 1 month, periodically thereafter
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: South Texas Accelerated Research Therapeutics (START)
state: Texas
Study officials:
References: